Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fdctech (FDCT) Shares Outstanding (Diluted Average) (2022 - 2025)

Fdctech has reported Shares Outstanding (Diluted Average) over the past 4 years, most recently at $422.6 million for Q3 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $422.6 million for Q3 2025, up 8.46% from a year ago — trailing twelve months through Sep 2025 was $422.6 million (up 8.46% YoY), and the annual figure for FY2024 was $389.9 million, up 18.33%.
  • Shares Outstanding (Diluted Average) for Q3 2025 was $422.6 million at Fdctech, roughly flat from $422.6 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for FDCT hit a ceiling of $422.6 million in Q2 2025 and a floor of $148.0 million in Q2 2022.
  • Median Shares Outstanding (Diluted Average) over the past 4 years was $361.1 million (2023), compared with a mean of $327.0 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): soared 125.36% in 2023 and later increased 8.46% in 2025.
  • Fdctech's Shares Outstanding (Diluted Average) stood at $158.0 million in 2022, then surged by 108.48% to $329.5 million in 2023, then grew by 18.33% to $389.9 million in 2024, then increased by 8.39% to $422.6 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $422.6 million (Q3 2025), $422.6 million (Q2 2025), and $422.2 million (Q1 2025) per Business Quant data.